◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Vicore Pharma Holding AB (publ) (VCRE) Financial History

Name: Vicore Pharma Holding AB (publ) (VCRE) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-09-08

Vicore Pharma Holding AB (publ) (VCRE) operates in the Biotechnology industry and is headquartered in Stockholm, Sweden with about 46 employees. Its market capitalization is roughly $326 million. In the fiscal year ended 2025-12-31, VCRE reported SEK 4M in revenue and (SEK 478M) in net income.

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden.

Interactive charts & full statements →

VCRE Revenue & Earnings History — Annual Income Statement

Income statement	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total Revenue	SEK 4M	SEK 109M	SEK 0M	SEK 0M	—
Gross Profit	SEK 4M	SEK 109M	SEK 0M	SEK 0M	—
Operating Income (EBIT)	(SEK 454M)	(SEK 190M)	(SEK 321M)	(SEK 288M)	—
Net Income	(SEK 478M)	(SEK 169M)	(SEK 311M)	(SEK 288M)	—

SEK; SEKM / SEKB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

VCRE Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31
Total Revenue	SEK 2M	SEK 1M	SEK 0M	—	SEK 2M	SEK 1M	—
Gross Profit	SEK 2M	SEK 1M	SEK 0M	—	SEK 2M	SEK 1M	—
Operating Income (EBIT)	(SEK 150M)	(SEK 124M)	(SEK 134M)	—	(SEK 111M)	(SEK 92M)	—
Net Income	(SEK 143M)	(SEK 109M)	(SEK 137M)	—	(SEK 115M)	(SEK 112M)	—

SEK; SEKM / SEKB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

VCRE Free Cash Flow History

VCRE Balance Sheet History

Balance sheet	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total Assets	SEK 1.2B	SEK 1.2B	SEK 498M	SEK 338M	—
Total Liabilities	SEK 123M	SEK 66M	SEK 42M	SEK 49M	—

SEK; SEKM / SEKB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive VCRE viewer.

Other Companies in Biotechnology

LYEL · Lyell Immunopharma, Inc. — $332 million
ABEO · Abeona Therapeutics Inc. — $331 million
UPB · Upstream Bio, Inc. — $329 million
CUVL · Clinuvel Pharmaceuticals Limited — $329 million
CLLS · Cellectis S.A. — $326 million
IMRX · Immuneering Corporation — $325 million
VNDA · Vanda Pharmaceuticals Inc. — $322 million
QTTB · Q32 Bio Inc. — $319 million

← VCRB All “V” companies VCRM →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.